Abstract: A method for distinguishing prostate cancer from prostatic hypertrophy using the method for analyzing PSA and an analysis kit of PSA are provided. An object of the present invention can be solved by being brought into contact a lectin having an affinity for p-N-acetylgalactosamine residues and/or a lectin having an affinity for fucose a(I, 2) galactose residues with a sample possibly containing PSA, to determine an amount of PSA having an affinity for the lectin. A method for distinguishing prostate cancer from prostatic hypertrophy can be provided by this method.

Abstract: A method of analyzing diagnostic information for estimating which of a benign prostate disease and prostate cancer is affecting a subject to be diagnosed combines two methods of analyzing diagnostic information. The first method includes measuring a concentration of a mucin-1 (Tn-MUC1), reactive with a lectin that recognizes and binds to an N-acetyl-D-galactosamine->serine(threonine) residue, in a subject blood sample, comparing the measured value with a threshold value, and estimating that a disease affecting the subject is benign prostate disease when the measured value is greater than the threshold value.

Abstract: A method of analyzing diagnostic information, the method including: measuring a concentration of a mucin-1 (Tn-MUC1), which is reactive with a lectin that recognizes and binds to an N-acetyl-D-galactosamine?serine (threonine) residue, in a blood sample originated from a subject to be diagnosed; comparing the measured value with a threshold value; and estimating that a disease affecting the subject to be diagnosed is not prostate cancer but a benign prostate disease when the measured value of the concentration of Tn-MUC1 is greater than the threshold value.

Abstract: A method of analyzing diagnostic information, the method including: measuring the concentration of all mucin-1s (total MUC1) in a blood sample originated from a subject to be diagnosed; comparing the measured value with a threshold value; and estimating that a disease affecting the subject to be diagnosed is not prostate cancer but a benign prostate disease when the measured value of the concentration of total MUC1 is greater than the threshold value.

Abstract: A method for distinguishing prostate cancer from prostatic hypertrophy using the method for analyzing PSA and an analysis kit of PSA are provided. An object of the present invention can be solved by being brought into contact a lectin having an affinity for ?-N-acetylgalactosamine residues with a sample possibly containing PSA, to determine an amount of PSA having an affinity for the lectin. A method for distinguishing prostate cancer from prostatic hypertrophy can be provided by this method.

Abstract: A method of analyzing diagnostic information, the method including: measuring a concentration of a mucin-1 (Tn-MUC1), which is reactive with a lectin that recognizes and binds to an N-acetyl-D-galactosamine?serine (threonine) residue, in a blood sample originated from a subject to be diagnosed; comparing the measured value with a threshold value; and estimating that a disease affecting the subject to be diagnosed is not prostate cancer but a benign prostate disease when the measured value of the concentration of Tn-MUC1 is greater than the threshold value.

Abstract: A method of analyzing diagnostic information, the method including: measuring the concentration of all mucin-1s (total MUC1) in a blood sample originated from a subject to be diagnosed; comparing the measured value with a threshold value; and estimating that a disease affecting the subject to be diagnosed is not prostate cancer but a benign prostate disease when the measured value of the concentration of total MUC1 is greater than the threshold value.

Abstract: A method for distinguishing prostate cancer from prostatic hypertrophy using the method for analyzing PSA and an analysis kit of PSA are provided. An object of the present invention can be solved by being brought into contact a lectin having an affinity for ?-N-acetylgalactosamine residues with a sample possibly containing PSA, to determine an amount of PSA having an affinity for the lectin. A method for distinguishing prostate cancer from prostatic hypertrophy can be provided by this method.

Abstract: A method for distinguishing prostate cancer from prostatic hypertrophy using the method for analyzing PSA and an analysis kit of PSA are provided. An object of the present invention can be solved by being brought into contact a lectin having an affinity for ?-N-acetylgalactosamine residues with a sample possibly containing PSA, to determine an amount of PSA having an affinity for the lectin. A method for distinguishing prostate cancer from prostatic hypertrophy can be provided by this method.

Abstract: The purpose of the present invention is to provide a method for detecting even mucin 1 derived from breast cancer, which cannot be detected by a CA15-3 measurement method. The purpose can be achieved by a method for analyzing the mucin 1 having a Sulfo-3Gal?1-3GalNAc-R carbohydrate chain, including: a step of bringing a 3? sulfonated core 1 carbohydrate chain binding probe capable of binding to the Sulfo-3Gal?1-3GalNAc-R carbohydrate chain into contact with a sample to be tested; a step of bringing a 3? sulfonated core 1 carbohydrate chain mucin 1 peptide binding probe capable of binding to the mucin 1 having a Sulfo-3Gal?1-3GalNAc-R carbohydrate chain or a mucin 1 binding probe capable of binding to a mucin 1 into contact with the sample to be tested; and a step of detecting a conjugate of the mucin 1 having a Sulfo-3Gal?1-3GalNAc-R carbohydrate chain and probe.

Abstract: The object of the present invention is to provide a method for detecting gastric cancer, and a kit for detecting gastric cancer. The object can be solved by a method for detecting gastric cancer characterized by analyzing ?1,4-N-acetylgalactosamine transferase 1. According to the present invention, gastric cancer patients can be detected at high rates, even early stage gastric cancer patients without a subjective symptom.

Abstract: The object of the present invention is to provide a clinical marker capable of distinguishing breast cancer from interstitial pneumonia; and a clinical marker for detecting malignancy or progress level of breast cancer, and for monitoring effects of the treatment of breast cancer. The object can be solved by a method for analyzing mucin 1 having Sia?2-8Sia?2-3Gal?-R, characterized by comprising the step of bringing a first probe specifically binding to a mucin 1 having Sia?2-8Sia?2-3Gal?-R into contact with a sample to be tested.

Abstract: A method for distinguishing prostate cancer from prostatic hypertrophy using the method for analyzing PSA and an analysis kit of PSA are provided. An object of the present invention can be solved by being brought into contact a lectin having an affinity for ?-N-acetylgalactosamine residues with a sample possibly containing PSA, to determine an amount of PSA having an affinity for the lectin. A method for distinguishing prostate cancer from prostatic hypertrophy can be provided by this method.

Abstract: The object of the present invention is to provide a method for detecting gynecologic cancer and a kit for detecting the same. The object can be solved by a method for detecting gynecologic cancer characterized in that ?1,3-galactosyltransferase-5 and/or ?1,3-galactosyltransferase-4, and GlcNAc 6-O-sulfotransferase-2 are analyzed. According to the detecting method, ovarian cancer and endometrial cancer patients can be detected at an early stage i.e. stages I and II, wherein patients have no subjective symptoms.

Abstract: A method for distinguishing prostate cancer from prostatic hypertrophy using the method for analyzing PSA and an analysis kit of PSA are provided. An object of the present invention can be solved by being brought into contact a lectin having an affinity for ?-N-acetylgalactosamine residues and/or a lectin having an affinity for fucose ?(1, 2) galactose residues with a sample possibly containing PSA, to determine an amount of PSA having an affinity for the lectin. A method for distinguishing prostate cancer from prostatic hypertrophy can be provided by this method.